These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39038919)

  • 1. Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.
    Wondergem NE; Miedema IHC; van de Ven R; Zwezerijnen GJC; de Graaf P; Karagozoglu KH; Hendrickx JJ; Eerenstein SEJ; Bun RJ; Mulder DC; Voortman J; Boellaard R; Windhorst AD; Hagers JP; Peferoen LAN; de Gruijl TD; Bloemena E; Brakenhoff RH; Leemans CR; Menke-van der Houven van Oordt CW
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39038919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
    Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
    Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
    Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of
    Kaira K; Kuji I; Kagamu H
    Cancer Imaging; 2021 Jan; 21(1):11. PubMed ID: 33441183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
    Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
    Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Vos JL; Zuur CL; Smit LA; de Boer JP; Al-Mamgani A; van den Brekel MWM; Haanen JBAG; Vogel WV
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2010-2022. PubMed ID: 34957526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
    Shah H; Wang Y; Cheng SC; Gunasti L; Chen YH; Lako A; Guenette J; Rodig S; Jo VY; Uppaluri R; Haddad R; Schoenfeld JD; Jacene HA
    JAMA Otolaryngol Head Neck Surg; 2022 Mar; 148(3):268-276. PubMed ID: 35050348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by
    Miedema IHC; Pouw JEE; Kwakman A; Zwezerijnen GJC; Huisman MC; Timmer FEF; van de Ven R; de Gruijl TD; Hospers GAP; de Langen AJ; Menke-van der Houven van Oordt CW
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38886117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
    Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
    Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
    Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
    JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
    Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
    World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Value of
    Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
    Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study.
    Gane E; Verdon DJ; Brooks AE; Gaggar A; Nguyen AH; Subramanian GM; Schwabe C; Dunbar PR
    J Hepatol; 2019 Nov; 71(5):900-907. PubMed ID: 31306680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
    Rosenberg AJ; Agrawal N; Juloori A; Cursio J; Gooi Z; Blair E; Chin J; Ginat D; Pasternak-Wise O; Hasina R; Starus A; Jones FS; Izumchenko E; MacCracken E; Wolk R; Cipriani N; Lingen MW; Pearson AT; Seiwert TY; Haraf DJ; Vokes EE
    JAMA Oncol; 2024 Jul; 10(7):923-931. PubMed ID: 38842838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
    Kelly RJ; Landon BV; Zaidi AH; Singh D; Canzoniero JV; Balan A; Hales RK; Voong KR; Battafarano RJ; Jobe BA; Yang SC; Broderick S; Ha J; Marrone KA; Pereira G; Rao N; Borole A; Karaindrou K; Belcaid Z; White JR; Ke S; Amjad AI; Weksler B; Shin EJ; Thompson E; Smith KN; Pardoll DM; Hu C; Feliciano JL; Anagnostou V; Lam VK
    Nat Med; 2024 Apr; 30(4):1023-1034. PubMed ID: 38504015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.